Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2003-06-03
2008-11-25
Hui, San-ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S180000, C514S181000, C514S182000
Reexamination Certificate
active
07456161
ABSTRACT:
A method for treating or preventing chronic obstructive pulmonary disease (COPD) by using as active agent a non-glucorticoid steroid, analogue thereof, such as dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S), or their salts, in an amount effective for preventing or treating COPD.
REFERENCES:
patent: 4393066 (1983-07-01), Garrett et al.
patent: 4499064 (1985-02-01), Shive
patent: 4501729 (1985-02-01), Boucher et al.
patent: 4575498 (1986-03-01), Holmes et al.
patent: 4628052 (1986-12-01), Peat
patent: 4920115 (1990-04-01), Nestler et al.
patent: 4931441 (1990-06-01), Lawrence
patent: 4985443 (1991-01-01), Montes
patent: 5021417 (1991-06-01), Prost
patent: 5059595 (1991-10-01), Le Grazie
patent: 5077284 (1991-12-01), Loria et al.
patent: 5110810 (1992-05-01), Eich et al.
patent: 5118505 (1992-06-01), Költringer
patent: 5162198 (1992-11-01), Eich et al.
patent: 5173488 (1992-12-01), Haeger
patent: 5177076 (1993-01-01), Nijkerk et al.
patent: 5266312 (1993-11-01), Leung et al.
patent: 5270305 (1993-12-01), Palmer
patent: 5347005 (1994-09-01), Mueller et al.
patent: 5407684 (1995-04-01), Loria et al.
patent: 5407927 (1995-04-01), Morales et al.
patent: 5489581 (1996-02-01), Daynes et al.
patent: 5527789 (1996-06-01), Nyce
patent: 5532230 (1996-07-01), Daynes et al.
patent: 5538734 (1996-07-01), Le Grazie
patent: 5583126 (1996-12-01), Daynes et al.
patent: 5635496 (1997-06-01), Daynes et al.
patent: 5660835 (1997-08-01), Nyce
patent: 5686438 (1997-11-01), Daynes et al.
patent: 5703063 (1997-12-01), Chasalow et al.
patent: 5767278 (1998-06-01), Gaeta et al.
patent: 5811418 (1998-09-01), Daynes et al.
patent: 5859000 (1999-01-01), Dowell et al.
patent: 5948434 (1999-09-01), Labrie
patent: 6087351 (2000-07-01), Nyce
patent: 6093706 (2000-07-01), Zeligs
patent: 6670349 (2003-12-01), Nyce
patent: 2002/0042401 (2002-04-01), Ferguson et al.
patent: 2003/0013772 (2003-01-01), Murphy et al.
patent: 2003/0138434 (2003-07-01), Campbell et al.
patent: 2003/0139331 (2003-07-01), Martin et al.
patent: 57-128624 (1982-08-01), None
patent: 52-99221 (1984-09-01), None
patent: WO 93/16704 (1993-09-01), None
patent: WO 96/16680 (1996-06-01), None
patent: WO 97/48367 (1997-12-01), None
patent: WO 98/03180 (1998-01-01), None
patent: WO 00/54763 (2000-09-01), None
patent: WO 01/15745 (2001-03-01), None
patent: WO 02/069955 (2002-09-01), None
patent: WO 03/072572 (2003-09-01), None
Merck Manual, 16th ed., 1992, p. 658-666.
Araneo et al., “Dehydroepiandrosterone Reduces Progressive Dermal Ischemia Caused by Thermal Injury”,J. Surg. Res.59(2):250-62 (1995).
Bonnett et al., “Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension,”PNAS100(16):9488-93 (2003).
Budavari, The Merck Index 11thed., 1989, pp. 660-661, monograph 4141.
Coleridge et al., “Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators”,Aust. N.Z. J. Med.23:348-54 (1993).
Dashtaki et al., “Dehydroepiandrosterone and Analogs Inhibit DNA Binding of AP-1 and Airway Smooth Muscle Proliferation1,”J. Pharmacol. Exp. Thera.285(2):876-83 (1998).
Dompeling et al., “Treatment with Inhaled Steroids in Asthma and Chronic Bronchitis: Long Term Compliance and Inhaler Technique”,Family Practice9(2):161-6 (1992).
Dunn, et al., “Dehydroepiandrosterone sulphate concentrations in asthmatic patients: pilot study,”N.Z. J. Med.97(768):805-8 (1984).
Dworski et al., “Conspectus: Inhaled Steroids in Asthma”,Comprehensive Therapy, 18:3 (1992).
Fehér et al., “Adrenocortical Function in Bronchial Asthma”,Acta Medica Hungarica40(2-3):125-32 (1983).
Fehér, et al., “Dehydroepiandrosterone Therapy of Patients with Corticosteroid Dependent Bronchial Asthma,”Natl. Institute of Rheumatism and Physiotherapy, in XIII Congress of the European Academy of Allergology and Clinical Immunology, eds.(Saba, et al., Debrecen Hungary (1986).
Hampl et al., “Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats,”J. Eur. Respir.21:862-5 (2003).
Holzmann et al., “Therapy of Psoriasis with Dehydroepiandrosterone-Enanthate. II. Intramuscular Depot Application of 300 mg”,Arch. Dermatol. Forsch.247(1):23-8 (1973) (German with English Abstract).
Hummel et al., “Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma”,The Lancet, 340(8834/8835):1483-7 (1992).
Itagaki et al., “Effect of Cortisol on the Release of Human Decidual”,Caplus, 114875 (1991) (Japanese with English Abstract).
Koó et al., “Our experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchical Asthma”,Orvosi Hetilap128(38):1995-7 (1987) (Hungarian).
Koó et al., “Our experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchical Asthma”,Orvosi Hetilap128(38):1995-7 (1987) (English translation).
Lejeune, “Pathogenesis of Mental Impairment in Trisomy 21”,Annales de Génétique, 92:27643 (1996) (French with English Abstract).
Mileva et al., “Androstenedione, DHEA sulfate, cortisol, aldosterone and testosterone in bronchial asthma patients”, 07608054 (1990) (Russian with English Abstract).
Pashko et al., “Inhibition of 7,12-dimethylbenz(a)anthracene-induced Skin Papillomas and Carcinomas by Dehydroepiandrosterone and 3-beta-methylandrost-5-en-17-one in mice”,Cancer Res.45(1):164-6 (1985).
Peeters et al., “Differences in Purine Metabolism in Patients with Down's Syndrome”,J. Intellect. Diabil. Res.37:471 (1993). Abstract.
Reed, “Aerosol Steroids as Primary Treatment of Mild Asthma”,New England J. Med., 325(6):425-6 (1991).
Rowe et al., “Effectiveness of Steroid Therapy in Acute Exacerbations of Asthma: A Meta-analysis”,Amer. J. Emergency Med., 10(4):301-10 (1992).
Sasaki et al., “Cervical Ripening with Dehydroepiandrosterone Sulphate”,Br. J. Obstet. Gynaecol.89(3):195-8, (1982).
Sciarra et al., “Aerosols”, Remington's Pharmaceutical Sciences, 18thed. (1990), Eds. Gennaro et al., pp. 1873-1875 and 1694-1712.
Sharma et al., “Screening of potential chemopreventive agents using biochemical markers of carcinogenesis”,Cancer Res.54(22):5848-55 (1994).
Shomali, “The Use of Anti-Aging Hormones. Melatonin. Growth Hormone, Testosterone, and Dehydroepiandrosterone: Consumer Enthusiasm for Unproven Therapies”,Md. Med. J.46(4):181-6 (1997).
Sonka et al., “Gout and Dehydroepiandrosterone: 3. DHEA Administration”,Endokrynologia Polska24(3):209-18 (1973).
Sur et al., “Double-blind trial pyroxidine (vitamin B6) in the treatment of steroid-dependent asthma”,Ann. Allergy, 70:147-52 (1993).
Schwartz et al., “Inhibition of 7,12-dimethylbenz[a]anthracene- and urethan-induced lung tumor formation in A/J mice by long-term treatment with dehydroepiandrosterone,”Carcinogenesis2(12):1335-7 (1981).
Van de Graaf et al., “Respiratory Membrane Permeability and Bronchial Hyperreactivity in Patients with Stable Asthma: Effects of Therapy with Inhaled Steroids”,Bronchial Asthma and Respiratory Membrane Permeability143:362-8 (1991).
Van Vollenhoven et al., “Dehydroepiandrosterone in SLE. Results of a Double-Blind, Placebo-Controlled, Randomized Clinical Trial.”,Arthritis Rheum.38(12): 1826-31 (1995).
Wolkowitz et al., “Dehydroepiandrosterone Treatment of Depression”,Biol. Psychiatry41(3):311-8. (1997).
Epigenesis Pharmaceuticals, LLC
Halluin Albert P.
Hui San-ming
Reamey Robert H.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Use of DHEA and DHEA-sulfate for the treatment of chronic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of DHEA and DHEA-sulfate for the treatment of chronic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of DHEA and DHEA-sulfate for the treatment of chronic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4021524